This site is intended for health professionals only
Tuesday 23 October 2018
Share |

Latest News

Lilly receives EU marketing authorisation for abemaciclib in metastatic breast cancer

Wednesday 17th October 2018

Eli Lilly and Company announced today that the European Commission has granted marketing authorisation (MA) for Verzenios® (abemaciclib) for the treatment of women with hormone receptor-positive (HR+), epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer, in combination with an aromatase inhibitor (AI) or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.1
Abemaciclibis an...